MLTX News and Press, MoonLake Immunotherapeutics From 07/21/22

Gainers: 1Life Healthcare ( ONEM ) +69% . Tabula Rasa HealthCare ( TRHC ) +52% . Vertical Aerospace ( EVTL ) +41% . Moon Lake Immuno therapeutics ( MLTX ) +32% . Altice USA ( ATUS ) +26% . Kaltura ( KLTR ) +22% . ...

Super Micro Computer ( SMCI ) +20% on better-than-expected Q4 prelim results. ToughBuilt Industries ( TBLT ) +16% . MoonLake Immunotherapeutics ( MLTX ) +14% . Visionary Education Technology Holdings ( VEDU ) +12% . Olema Pharmaceuti...

Cowen analyst Phil Nadeau initiated coverage of MoonLake Immunotherapeutics ( MLTX ) with an Outperform rating. The company is developing sonelokimab in inflammatory diseases and Phase 2 data in psoriasis suggest improved safety and efficacy compared to traditional anti-IL-17...

Gainers: Helius Medical Technologies (HSDT) +57%. Tonix Pharmaceuticals  TNXP +49%. NeuroOne Medical Technologies (NMTC) +16%. Oncternal Therapeutics (ONCT) +16%. Butterfly Network (BFLY) +15%. Losers: Enochian Biosciences ENOB -37%. Icosavax ...

MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company that specializes in therapies for inflammatory skin and joint diseases, saw its shares jump 41.1% on Tuesday. The stock closed at $6.38 on Friday, then opened at $7.55 on Tuesday after the Memorial Da...

Gainers: TherapeuticsMD (TXMD) +355%. MoonLake Immunotherapeutics (MLTX) +24%. Gritstone bio (GRTS) +18%. Nurix Therapeutics (NRIX) +10%. DexCom (DXCM) +9%. Losers: Outlook Therapeutics (OTLK) -54%. Elevation Oncology (ELEV) -18%. SIGA Technologies (SIGA) -1...

Switzerland-based MoonLake Immunotherapeutics (NASDAQ:MLTX) said the first patient was dosed at a U.S. site of its global phase 2 trial of investigational Nanobody sonelokimab to treat patients with moderate-to-severe hidradenitis suppurativa (HS). HS is a condition causing sma...

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa First Phase 2 trial in hidradenitis suppurativa using the higher clinical response level of HiSCR75 as the primary endpoint ...